ASPIRA PATHLAB & DIAGNOSTICS | MEDINOVA DIAG. | ASPIRA PATHLAB & DIAGNOSTICS / MEDINOVA DIAG. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.4 | 19.7 | - | View Chart |
P/BV | x | 2.6 | - | - | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS MEDINOVA DIAG. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
MEDINOVA DIAG. Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / MEDINOVA DIAG. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 38 | 195.3% | |
Low | Rs | 26 | 18 | 146.5% | |
Sales per share (Unadj.) | Rs | 14.0 | 10.0 | 140.3% | |
Earnings per share (Unadj.) | Rs | -0.1 | 1.7 | -5.2% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 2.0 | 72.9% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | -5.1 | -240.8% | |
Shares outstanding (eoy) | m | 10.29 | 9.98 | 103.1% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 2.8 | 128.3% | |
Avg P/E ratio | x | -583.7 | 16.8 | -3,483.2% | |
P/CF ratio (eoy) | x | 34.6 | 14.0 | 246.9% | |
Price / Book Value ratio | x | 4.1 | -5.4 | -74.8% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 279 | 185.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 20 | 282.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 100 | 144.7% | |
Other income | Rs m | 3 | 2 | 142.7% | |
Total revenues | Rs m | 148 | 102 | 144.6% | |
Gross profit | Rs m | 16 | 26 | 60.2% | |
Depreciation | Rs m | 16 | 3 | 486.5% | |
Interest | Rs m | 4 | 6 | 64.5% | |
Profit before tax | Rs m | -1 | 19 | -4.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 2 | 0.0% | |
Profit after tax | Rs m | -1 | 17 | -5.3% | |
Gross profit margin | % | 11.0 | 26.5 | 41.6% | |
Effective tax rate | % | 0 | 12.4 | -0.0% | |
Net profit margin | % | -0.6 | 16.7 | -3.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 17 | 346.3% | |
Current liabilities | Rs m | 16 | 36 | 44.1% | |
Net working cap to sales | % | 29.5 | -19.0 | -155.3% | |
Current ratio | x | 3.7 | 0.5 | 784.6% | |
Inventory Days | Days | 88 | 25 | 350.3% | |
Debtors Days | Days | 590 | 257 | 230.0% | |
Net fixed assets | Rs m | 115 | 22 | 513.9% | |
Share capital | Rs m | 103 | 100 | 103.4% | |
"Free" reserves | Rs m | 25 | -151 | -16.3% | |
Net worth | Rs m | 128 | -51 | -248.2% | |
Long term debt | Rs m | 10 | 58 | 16.7% | |
Total assets | Rs m | 173 | 39 | 441.8% | |
Interest coverage | x | 0.8 | 3.9 | 20.0% | |
Debt to equity ratio | x | 0.1 | -1.1 | -6.7% | |
Sales to assets ratio | x | 0.8 | 2.5 | 32.7% | |
Return on assets | % | 1.9 | 58.9 | 3.2% | |
Return on equity | % | -0.7 | -32.4 | 2.1% | |
Return on capital | % | 2.4 | 414.8 | 0.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 14 | -0.8% | |
From Investments | Rs m | 2 | -3 | -46.8% | |
From Financial Activity | Rs m | -9 | -9 | 109.5% | |
Net Cashflow | Rs m | -8 | 2 | -350.2% |
Indian Promoters | % | 18.7 | 62.1 | 30.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 37.9 | 214.7% | |
Shareholders | 1,512 | 10,295 | 14.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | MEDINOVA DIA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.14% | 4.99% | 0.45% |
1-Month | -8.93% | 23.93% | 2.55% |
1-Year | -3.33% | 84.95% | 56.14% |
3-Year CAGR | 1.86% | 9.12% | 15.22% |
5-Year CAGR | -1.91% | 20.23% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the MEDINOVA DIA share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of MEDINOVA DIA the stake stands at 62.1%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of MEDINOVA DIA.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
MEDINOVA DIA paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of MEDINOVA DIA.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.